Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.73 million
Profitability
Miscellaneous
Employees6
OptionableNot Optionable
Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions
What is Checkpoint Therapeutics' stock symbol?
Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
How were Checkpoint Therapeutics' earnings last quarter?
Checkpoint Therapeutics Inc (NASDAQ:CKPT) issued its earnings results on Friday, November, 2nd. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.06. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.26 million. Checkpoint Therapeutics had a negative return on equity of 139.01% and a negative net margin of 3,800.00%. View Checkpoint Therapeutics' Earnings History.
When is Checkpoint Therapeutics' next earnings date?
What price target have analysts set for CKPT?
1 analysts have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their predictions range from $11.00 to $11.00. On average, they expect Checkpoint Therapeutics' share price to reach $11.00 in the next year. This suggests a possible upside of 205.6% from the stock's current price. View Analyst Price Targets for Checkpoint Therapeutics.
What is the consensus analysts' recommendation for Checkpoint Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Checkpoint Therapeutics.
What are Wall Street analysts saying about Checkpoint Therapeutics stock?
Here are some recent quotes from research analysts about Checkpoint Therapeutics stock:
- 1. According to Zacks Investment Research, "Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. " (1/4/2019)
- 2. HC Wainwright analysts commented, "Our $26 price target comprises $24/share for Korsuva in CKD-aP plus $2/share in optionality for the CR845 in post-surgical pain or PONV. Our CKD-aP valuation assumes an IV Korsuva launch in 2021 with peak U.S sales of approximately $550M, and oral Korsuva 30% probability of 2023 launch and $300M peak U.S. sales (<$100M 30% risk- adjusted sales in our model now). Our $24/share DCF assumes overall 75% probability of success in CKD-aP (oral still at 30%) with an 11.5% WACC discount and 0% terminal growth beyond 2028. A DCF with IV projections entirely de-risked (oral still at 30%), all else equal, would yield a CDK-aP value of $32/share."" (8/8/2018)
Has Checkpoint Therapeutics been receiving favorable news coverage?
News headlines about CKPT stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Checkpoint Therapeutics' key competitors?
Some companies that are related to Checkpoint Therapeutics include BioSpecifics Technologies (BSTC), Prothena (PRTA), Forty Seven (FTSV), Innate Pharma (IPHYF), Odonate Therapeutics (ODT), Corium International (CORI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Eidos Therapeutics (EIDX), Akorn (AKRX), Clementia Pharmaceuticals (CMTA), Evolus (EOLS), Corbus Pharmaceuticals (CRBP), Beyondspring (BYSI) and ZEALAND PHARMA/S (ZEAL).
Who are Checkpoint Therapeutics' key executives?
Checkpoint Therapeutics' management team includes the folowing people:
- Mr. James F. Oliviero III, CEO, Pres & Director (Age 42)
- Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 31)
- Ms. Robyn M. Hunter, Corp. Sec. (Age 56)
Who are Checkpoint Therapeutics' major shareholders?
Which institutional investors are buying Checkpoint Therapeutics stock?
How do I buy shares of Checkpoint Therapeutics?
Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Checkpoint Therapeutics' stock price today?
One share of CKPT stock can currently be purchased for approximately $3.60.
How big of a company is Checkpoint Therapeutics?
Checkpoint Therapeutics has a market capitalization of $121.20 million and generates $1.73 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Checkpoint Therapeutics employs 6 workers across the globe.
What is Checkpoint Therapeutics' official website?
How can I contact Checkpoint Therapeutics?
Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
